agrippal vaccine suspension for injection 0.5ml pre-filled syringes
seqirus uk ltd - influenza virus surface antigens - suspension for injection
imuvac vaccine suspension for injection 0.5ml pre-filled syringes
viatris uk healthcare ltd - influenza virus surface antigens - suspension for injection
quadrivalent influenza vaccine (split virion, inactivated) suspension for injection 0.5ml pre-filled syringes
split virion, inactivated) suspension for injection 0.5ml pre-filled syringes (sanofi - influenza virus split virion - suspension for injection
virus plus (influenzinum- 2017-2018, adenoviren nosode, herpes simplex 1 nosode, herpes simplex 2 nosode, cytomegalovirus nosode
deseret biologicals, inc. - influenza a virus a/singapore/gp1908/2015 ivr-180a (h1n1) antigen (propiolactone inactivated) (unii: 9jwn7vdq7n) (influenza a virus a/singapore/gp1908/2015 ivr-180a (h1n1) hemagglutinin antigen (propiolactone inactivated) - unii:u6c4gj6wzg), influenza a virus a/hong kong/4801/2014 x-263b (h3n2) antigen (propiolactone inactivated) (unii: 3dzy3q314e) (influenza a virus a/hong kong/4801/2014 x-263b (h3n2) hemagglutinin antigen (propiolactone inactivated) - unii:c2c4da5k06), influenza b virus b/brisbane/60/20 - influenza a virus a/singapore/gp1908/2015 ivr-180a (h1n1) antigen (propiolactone inactivated) 12 [hp_x] in 1 ml - for temporary relief of symptoms related to general viral infection (such as influenza, epstein-barr virus [ebv], cytomegalovirus [cmv], hepatitis, herpes, or adenovirus) including fever, fatigue, muscle aches and pain, rash, cold sores, headache and confusion.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration. for temporary relief of symptoms related to general viral infection (such as influenza, epstein-barr virus [ebv], cytomegalovirus [cmv], hepatitis, herpes, or adenovirus) including fever, fatigue, muscle aches and pain, rash, cold sores, headache and confusion.** **these statements are based upon traditional homeopathic principles. they have not been reviewed by the food and drug administration.
supemtek
sanofi pasteur - influenza a virus subtype h1n1 haemagglutinin, recombinant, influenza a virus subtype h3n2 haemagglutinin, recombinant, influenza b virus victoria lineage haemagglutinin, recombinant, influenza b virus yamagata lineage haemagglutinin, recombinant - influenza, human - vaccines - supemtek is indicated for active immunization for the prevention of influenza disease in adults.supemtek should be used in accordance with official recommendations.
foclivia
seqirus s.r.l. - influenza virus surface antigens, inactivated: a/viet nam/1194/2004 (h5n1) - influenza, human; immunization; disease outbreaks - influenza vaccines - prophylaxis of influenza in an officially declared pandemic situation.pandemic influenza vaccine should be used in accordance with official guidance.
duramune adult c4 canine distemper, adenovirus, parainfluenza & parvovirus live vaccine
boehringer ingelheim animal health australia pty. ltd. - canine adeno virus type 2; canine distemper virus; canine parainfluenza type 2; canine parvo virus - misc. vaccines or anti sera - canine adeno virus type 2 vaccine-viral active 0.0 p; canine distemper virus vaccine-viral active 0.0 p; canine parainfluenza type 2 vaccine-viral active 0.0 p; canine parvo virus vaccine-viral active 0.0 p - immunotherapy - dog - over 6 weeks old - canine adenovirus - type 2 | canine distemper | canine parainfluenza | canine parvovirus | parvovirus
duramune adult c3 canine distemper, adenovirus & parvovirus live vaccine
boehringer ingelheim animal health australia pty. ltd. - canine adeno virus type 2; canine distemper virus; canine parvo virus - misc. vaccines or anti sera - canine adeno virus type 2 vaccine-viral active 0.0 p; canine distemper virus vaccine-viral active 0.0 p; canine parvo virus vaccine-viral active 0.0 p - immunotherapy - dog - over 6 weeks old - canine adenovirus - type 1 | canine adenovirus - type 2 | canine distemper | canine parvovirus | parvovirus
inflexal v
crucell italy s.r.l. - a/california/7/2009 (h1n1) - derived strain used nymc x-181 reass a/california/7/2009 (h1n1) - derived strain used nymc x-181 reass b/brisbane/60/2008 - like strain (b/brisbane/60/2008) - suspension for injection - 15 microgram
protech c2i canine coronavirus & leptospira copenhageni killed vaccine
boehringer ingelheim animal health australia pty. ltd. - leptospira icterohaemorrhagiae antigen; canine coronavirus vaccine - antigen - misc. vaccines or anti sera - leptospira icterohaemorrhagiae antigen vaccine-antigen active 1.0 rp; canine coronavirus vaccine - antigen vaccine-viral active 1.62 rp - immunotherapy - dog - over 6 weeks old - canine adenovirus - type 1 | canine adenovirus - type 2 | canine coronavirus | canine distemper | canine parainfluenza | canine parvovirus | leptospira icterohaemorrhagiae | parvovirus